Royalty Pharma plc (RPRX)
Royalty Pharma plc (RPRX) from its SEC filings: 2025 revenue $2.4 billion (+5% vs the year before), net margin 32%, free cash flow $2.5 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $2.4 billion |
| Revenue growth | +5% |
| Net income | $770.9 million |
| Net margin | 32.4% |
| Free cash flow | $2.5 billion |
| Diluted EPS | $1.78 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +16% |
| Cash | $812.0 million |
| Long-term debt | $8.6 billion |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.